Diabetic Dyslipidemia Review: An Update on Current Concepts and Management Guidelines of Diabetic Dyslipidemia

American Journal of the Medical Sciences

Volumn 351, Issue 4, 2016, Pages 361-365

  Dake, Andrew W ^a   Sora, Nicoleta D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cholesterol; Diabetes; Guideline; Lipid

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; ANTILIPEMIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; HUMAN; MONITORING; PRACTICE GUIDELINE; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DYSLIPIDEMIAS; RISK FACTOR; STANDARDS;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DISEASE MANAGEMENT; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84987624998     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2016.01.020     Document Type: Article

References (18)

1. 1 Center for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf; 2014 Accessed 20.10.15.
2. 2 Jaiswal, M., Schinske, A., Pop-Busui, R., Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab 28:3 (2014), 325–338.
3. 3 Cardovacular Disease and Diabetes. American Heart Association Website. http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.VqfJL5orKUk. Accessed 2601.16.
4. 4 Wu, L., Parhofer, K.G., Diabetic dyslipidemia. Metabolism 63:12 (2014), 1469–1479.
5. 5 Cholesterol Treatment Trialists’ (CTT) Collaboration, Biagen, C., Blackwell, L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:9753 (2010), 1670–1681.
6. 6 Ng, D.S., Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes 37:5 (2013), 319–326.
7. 7 Chehade, J.M., Gladysz, M., Mooradian, A.D., Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 73:4 (2013), 327–339.
8. 8 Carmena, R., Duriesz, P., Fruchart, J.C., Atherogenic lipoprotein particles in atherosclerosis. Circulation 109:23 suppl 1 (2004), S1112–S1117.
9. 9 Grundy, S.M., Cleeman, J.I., Merz, C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110:2 (2004), 227–239.
10. 10 Jellinger, P.S., Smith, D.A., Mehta, A.E., et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 18:suppl 1 (2012), S1–S78.
11. 11 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25 Pt B (2014), 2889–2934.
12. 12 2013 Prevention Guideline Tools: CV Risk Calculator. American Heart Association Website. http://my.americanheart.org/cvriskcalculator. Accessed 28.10.15.
13. 13 American Diabetes Association, Standards of medical care in diabetes—2015. Diabetes Care 38:suppl 1 (2015), S1–S99.
14. 14 Ahmad, Z., Statin intolerance. Am J Cardiol 113:10 (2014), 1765–1771.
15. 15 Sattar, N.A., Ginsberg, H., Ray, K., et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl 15:1 (2014), 1–15.
16. 16 Chan, D.C., Pang, J., Watts, G.F., Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?. Curr Atheroscler Rep, 17(1), 2015, 472.
17. 17 Mogadam, M., Do statins increase the risk of diabetes or is it guilt by association?. Curr Opin Endocrinol Diabetes Obes 21:2 (2014), 140–145.
18. 18 Brault, M., Ray, J., Gomez, Y.H., et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63:6 (2014), 735–745.